Investigators at Samsung Bioepis Co. Ltd. Detail Findings in Antiangiogenic Ophthalmic Agents [Physicochemical and Biological Stability Assessment of Sb11 (Ranibizumab Biosimilar) Under Ambient and In-use Storage for Intravitreal Administration]

Press/Media: Press / Media

Period2023 Feb 15

Media coverage

1

Media coverage

  • TitleInvestigators at Samsung Bioepis Co. Ltd. Detail Findings in Antiangiogenic Ophthalmic Agents [Physicochemical and Biological Stability Assessment of Sb11 (Ranibizumab Biosimilar) Under Ambient and In-use Storage for Intravitreal Administration]
    Media name/outletAngiogenesis Daily
    Country/TerritoryUnited States
    Date23/2/15
    URLct.moreover.com/?a=50019863782&p=1gw&v=1&x=9siySepkqBm-i48LXivIUw
    Personsjin woo Park
View all 1
View less